Impaired endothelium-dependent vasodilatation in subclinical hypothyroidism: Beneficial effect of levothyroxine therapy

Journal of Clinical Endocrinology and Metabolism

Volumn 88, Issue 8, 2003, Pages 3731-3737

  Taddei, Stefano ^a   Caraccio, Nadia ^a   Virdis, Agostino ^a   Dardano, Angela ^a   Versari, Daniele ^a   Ghiadoni, Lorenzo ^a   Salvetti, Antonio ^a   Ferrannini, Ele ^a   Monzani, Fabio ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; CHOLESTEROL; LEVOTHYROXINE; N(G) METHYLARGININE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE INHIBITOR; NITROPRUSSIDE SODIUM; VASODILATOR AGENT;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DYSLIPIDEMIA; ENDOTHELIUM CELL; ENDOTHELIUM LESION; EUTHYROIDISM; FEMALE; FOREARM BLOOD FLOW; HASHIMOTO DISEASE; HORMONE SUBSTITUTION; HUMAN; HYPOTHYROIDISM; MALE; PLETHYSMOGRAPHY; PRIORITY JOURNAL; SUBCLINICAL HYPOTHYROIDISM; VASCULAR ENDOTHELIUM; VASCULAR RESISTANCE;

ACETYLCHOLINE; ADULT; ENDOTHELIUM, VASCULAR; ENZYME INHIBITORS; FEMALE; HUMANS; HYPOTHYROIDISM; IODIDE PEROXIDASE; LIPIDS; LIPOPROTEINS, LDL; MALE; NITRIC OXIDE; NITRIC OXIDE DONORS; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE III; NITROPRUSSIDE; OMEGA-N-METHYLARGININE; REGIONAL BLOOD FLOW; THYROGLOBULIN; THYROID HORMONES; THYROIDITIS, AUTOIMMUNE; THYROXINE; VASCULAR RESISTANCE; VASODILATION; VASODILATOR AGENTS;

EID: 0041883173     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.2003-030039     Document Type: Article

References (36)

1. Surks MI, Ocampo E 1996 Subclinical thyroid disease. Am J Med 100:217-223
2. Canaris GJ, Manowitz NR, Mayor G, Ridgway EC 2000 The Colorado thyroid disease prevalence study. Arch Intern Med 160:526-534
3. Cooper DS, Halpern R, Wood LC, Levin AA, Ridgway EC 1984 L-thyroxine therapy in subclinical hypothyroidism. A double-blind, placebo-controlled trial. Ann Intern Med 101:18-24
4. Monzani F, Del Guerra P, Caraccio N, Pruneti CA, Pucci E, Luisi M, Banchieri L 1993 Subclinical hypothyroidism: neurobehavioural features and beneficial effect of L-thyroxine treatment. Clin Investig 71:367-371
5. 4 replacement therapy. Clin Endocrinol (Oxf) 51:237-242
6. Chu JW, Crapo LM 2001 Clinical perspective. The treatment of subclinical hypothyroidism is seldom necessary. J Clin Endocrinol Metab 86:4591-4599
7. Bastenie PA, Vanhaelst L, Bonnyns M, Neve P, Staquet M 1971 Preclinical hypothyroidism: a risk factor for coronary heart-disease. Lancet 1:203-204
8. Bastenie PA, Vanhaelst L, Glodstein J, Smets P 1977 Asymptomatic autoimmune thyroiditis and coronary heart-disease. Cross-sectional and prospective studies. Lancet 2:155-158
9. Caraccio N, Ferrannini E, Monzani F 2002 Lipoprotein profile in subclinical hypothyroidism: effect of levothyroxine replacement therapy. A randomized, placebo-controlled study. J Clin Endocrinol Metab 87:1533-1538
10. Meier C, Staub JJ, Roth CB, Guglielmetti M, Kunz M, Miserez AR, Drewe J, Huber P, Herzog R, Muller B 2001 TSH-controlled L-thyroxine therapy reduces cholesterol levels and clinical symptoms in subclinical hypothyroidism: a double blind, placebo-controlled trial (Basel Thyroid Study). J Clin Endocrinol Metab 86:4860-4866
11. Tzotzas T, Krassas GE, Konstantinidis T, Bougoulia M 2000 Changes in lipoprotein(a) levels in overt and subclinical hypothyroidism before and during treatment. Thyroid 10:803-808
12. Hak AE, Pols HAP, Visser TJ, Drexhage HA, Hofman A, Witteman JC 2000 Subclinical hypothyroidism is an independent risk factor for atherosclerosis and myocardial infarction in elderly women. The Rotterdam Study. Ann Intern Med 132:270-278
13. Mathews JD, Whittingham S, Mackay IR 1974 Autoimmune mechanism in human vascular disease. Lancet 2:1423-1427
14. Masaki H, Nishikawa M, Urakami M, Yoshimura M, Toyoda N, Mori Y, Yoshikawa N, Inada M 1992 3,3′,5′-Triiodothyronine inhibits collagen-induced human platelet aggregation. J Clin Endocrinol Metab 75:721-725
15. Chadarevian R, Bruckert E, Ankri A, Beucler I, Giral P, Turpin G 1998 Relationship between thyroid hormones and d-dimer levels. Thromb Haemost 79:99-103
16. Luscher TF, Vanhoutte PM 1990 The endothelium: modulator of cardiovascular function. Boca Raton, FL: CRC Press; 1-215
17. Furchgott RF, Zawadzky JV 1980 The obligatory role of endothelial cells in the relaxation of artherial smooth muscle by acetylcholine. Nature 288:373-376
18. Palmer RMJ, Ferrige AG, Moncada S 1987 Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 327:524-526
19. Palmer RMJ, Ashton DS, Moncada S 1988 Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature 333:664-666
20. Bredt DS, Hwang PM, Glatt CE, Lowenstein C, Reed RR, Snyder SH 1991 Cloned and expressed nitric oxide synthase structurally resembles cytochrome P-450 reductase. Nature 351:714
21. Taddei S, Virdis A, Ghiadoni L, Magagna A, Salvetti A 1998 Vitamin C improves endothelium-dependent vasodilation by restoring nitric oxide activity in essential hypertension. Circulation 97:2222-2229
22. Suwaidi JA, Hamasaki S, Higano ST, Nishimura RA, Holmes Jr DR, Lerman A 2000 Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation 101:948-954
23. Schacetylcholineinger V, Britten MB, Zeiher AM 2000 Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 101:1899-1906
24. Heitzer T, Schlinzig T, Krohn K, Meinertz T, Munzel T 2001 Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation 104:2673-2678
25. Whitney RJ 1953 The measurement of volume changes in human limbs. J Physiol (Lond) 121:1-27
26. Vallance P, Collier J, Moncada S 1989 Effect of endothelium-derived nitric oxide on peripheral arteriolar tone in man. Lancet 2:997-1000
27. Stroes ESG, Lüscher TF, de Groot FG, Koomans HA, Rabelink TJ 1997 Cyclosporin A increases nitric oxide activity in vivo. Hypertension 29:570-575
28. Schultz KD, Schultz K, Schultz G 1977 Sodium nitroprusside and other smooth muscle relaxants increase cyclic GMP levels in rat ductus deferens. Nature 265:750-751
29. Folkow B 1995 The structural factor in hypertension with special emphasis on the altered geometric design of the systemic arteries. In: Laragh JH, Brenner BM, eds. Hypertension: pathophysiology, diagnosis and treatment. New York: Raven Press; 481-502
30. Pedrinelli R, Taddei S, Spessot M, Salvetti A 1987 Maximal postischemic forearm vasodilation in human hypertension: a reassessment of the method. J Hypertens Suppl 5:S431-S433
31. Anderson TJ 1999 Assessment and treatment of endothelial dysfunction in humans. J Am Coll Cardiol 34:631-638
32. Creager MA, Cooke JP, Mendelsohn ME, Gallagher SJ, Coleman SM, Loscalzo J, Dzau VJ 1990 Impaired vasodilation of forearm resistance vessel in hypercholesterolemic humans. J Clin Invest 86:228-234
33. Andersen S, Pedersen KM, Bruun NH, Laurberg P 2002 Narrow individual variations in serum T(4) and T(3) in normal subjects: a clue to the understanding of subclinical thyroid disease. J Clin Endocrinol Metab 87:1068-1072
34. Lekakis J, Papamichael C, Alevizaki M, Piperingos G, Marafelia P, Mantzos J, Stamatelopoulos S, Koutras DA 1997 Flow-mediated, endothelium-dependent vasodilation is impaired in subjects with hypothyroidism, borderline hypothyroidism, and high-normal serum thyrotropin (TSH) values. Thyroid 7:411-414
35. Fichtlscherer S, Rosenberger G, Walter DH, Breuer S, Dimmeler S, Zeiher AM 2000 Elevated C-reactive protein levels and impaired endothelial vasoreactivity in patients with coronary artery disease. Circulation 102:1000-1006
36. Kugiyama K, Doi H, Motoyama T, Motoyama T, Soejima H, Misumi K, Kawano H, Nakagawa O, Yoshimura M, Ogawa H, Matsumura T, Sugiyama S, Nakano T, Nakajima K, Yasue H 1998 Association of remnant lipoprotein levels with impairment of endothelium-dependent vasomotor function in human coronary arteries. Circulation 97:2519-2526